Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • howcomethisdoesnotwork howcomethisdoesnotwork Apr 14, 2013 5:47 PM Flag

    Better Subset Based on Trials Possible as Outcome, meeting most end-points

    What if the Technosphere technology works fine, and each patient carries a backup insulin injection pen in the event of a failure, much like the Epi-Pens. This product may be approved for a subset of the population, and as more clinical evidence becomes known over 1-2 years of Phase IV studies, and further research, its customer base expands.
    Maybe there is a way to meet the best of both worlds and reduce or refine the subset of the population that can use this insulin inhaler.
    The share prices could then potentially hit $ 20.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MNKD
4.15-0.01(-0.24%)Aug 4 4:00 PMEDT